Crossmark

Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Crossref DOI link: https://doi.org/10.1016/j.pulmoe.2020.08.007

Published Online: 2025-03-10

Published Print: 2021-03-30

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Barata, F.

Queiroga, H.

Teixeira, E.

Almodovar, T.

Soares, M.

Parente, B.

Mellidez, J.C.

Alves, P.

Antunes, A.
Funding

Funding for this research was provided by:

Roche
License Information

Version of Record valid from 2021-03-30
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tpul20

Publication History

Received: 2019-11-06

Published: 2025-03-10

Document is current

Any future updates will be listed below